Everything below concerns ACTH(4-10). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
== Interaction with other cells == Within the epidermis keratinocytes are associated with other cell types such as melanocytes and Langerhans cells. Keratinocytes form tight junctions with the nerves of the skin and hold the Langerhans cells and intra-dermal lymphocytes in position within the epidermis. Keratinocytes also modulate the immune system: apart from the above-mentioned antimicrobial peptides and chemokines they are also potent producers of anti-inflammatory mediators such as IL-10 and TGF-β. When activated, they can stimulate cutaneous inflammation and Langerhans cell activation via TNFα and IL-1β secretion. Keratinocytes contribute to protecting the body from ultraviolet radiation (UVR) by taking up melanosomes, vesicles containing the endogenous photoprotectant melanin, from epidermal melanocytes. Each melanocyte in the epidermis has several dendrites that stretch out to connect it with many keratinocytes. The melanin is then stored within keratinocytes and melanocytes in the perinuclear area as supranuclear "caps", where it protects the DNA from UVR-induced damage.
== Medical uses == Elagolix is used in the treatment of moderate to severe pain associated with endometriosis in premenopausal women. Endometriosis is a condition in which the endometrium, the inner lining of the uterus, grows outside of the uterus into surrounding tissues and causes symptoms such as pelvic pain and infertility. Around 10% of women may be affected by endometriosis. Elagolix significantly decreases symptoms of dysmenorrhea (menstrual pelvic pain), non-menstrual pelvic pain, and dyspareunia (pain during sexual intercourse) in women with endometriosis. The medication is used at a lower dosage of 150 mg once per day or at a higher dosage of 200 mg twice per day, depending on the severity of symptoms. The effectiveness of elagolix in the treatment of symptoms of endometriosis was demonstrated in the 6-month Elaris Endometriosis I and II (EM-I and EM-II) phase III clinical trials. In Elaris EM-I, the percentage of women who had a clinical response with respect to dysmenorrhea was 46.4% in the lower-dose elagolix group and 75.8% in the higher-dose elagolix group, as compared with 19.6% in the placebo group; in Elaris EM-II, the corresponding percentages were 43.4% and 72.4%, as compared with 22.7% (P < 0.001 for all comparisons).
=== Sweat gland nerve fiber density === Sweat gland nerve fiber density (SGNFD) can be quantified in skin biopsies taken from the distal leg, distal thigh, and proximal thigh prepared for standard analysis of intraepidermal nerve fiber density (IENFD). Nerve fibers innervating sweat glands are stained with Protein Gene Product 9.5 and quantified using manual morphometry with light microscopy. SGNFD can potentially be used as a surrogate anatomical marker for sudomotor function. However, it is not a direct assessment of the sweat response, and normative data must be established.
== Awards == Awards for his work include the Award of Society of Polymer Science, Japan (1982), The Chemical Society of Japan Award for 1999, Chirality Medal (2001), Medal with Purple Ribbon (Japanese Government) (2002), Fujiwara Prize (2005), and the Japan Prize (2019). In 2020, he became a laureate of the Asian Scientist 100 by the Asian Scientist.
Sources: en.wikipedia.org
[we are] cleaning the affront of the traitors who broke their word and oaths and acted without hesitation against Masonic democracy." Sergio Rafael Vidal Águila stated that the decision was: "...not only an act of justice, but of restoration, because it was very difficult to accept those persons as deserving of membership… because of what it represents that they violated their oaths without shame and were part of what, without a doubt, was not only a collection of ambitions but the service of outdated men in the shadow of a political power that used them to persecute Freemasons within the Institution itself." The Court also affirmed that the actions of the protestors on June 5, 2025 were in their eyes a legitimate attempt to restore institutional order. The expulsions were submitted pending their ratification at the semi-annual meeting of the High Chamber of the Grand Lodge of Cuba, in September 2026.
=== 1950s onward === The advent in the 1950s of fibrous synthetics such as nylon, polyethylene, polypropylene, and polyvinyls provided new materials from which researchers and doctors in the field of wound care could explore better protecting of healing wounds and even accelerating the natural wound healing process. In the 1960s, research and articles by George Winter and Howard Maibach reported on the superior efficacy of moist wound dressings. The adoption of moist wound dressing technique as recommended best wound dressing practice reflected a large advance in approach producing markedly superior clinical outcomes. This dawn of modern wound care treatment initiated a process of improvement in the clinician's ability to bolster wound-site re-epithelialization and healing. The focus on evidence-based best practices and research continues. In the 1990s, improvements in composite and hybrid polymers expanded the range of materials available for wound dressing. Grafting and biotechnology have produced usable and useful protective covering of actual human skin generated through cloning procedures. These improvements, coupled with the developments in tissue engineering, have given rise to a number of new classes of wound dressings. One of these, "living skin equivalents," is often cited as a misnomer because they lack key components of whole living skin. "Living skin equivalents" may have the potential to serve as cellular platforms for the release of growth factors essential for proper wound healing.
=== Mechanism of action === Nitrogen containing bisphosphonates, which include ibandronate, pamidronate and alendronate exert their effects on osteoclasts mainly by inhibiting the synthesis of isoprenoid lipids such as isopentenyl diphosphate (IPP), farnesyl diphosphate (FPP), and geranylgeranyl diphosphate (GGPP) via the mevalonate pathway. These isoprenoids are used in posttranslational modification(prenylation) of small GTPases such as Ras, Rho, and Rac. These prenylated GTPases are necessary for various cellular processes including osteoclast morphology, endosome trafficking, and apoptosis. Alendronate has also been shown to impair the function of osteclast lysosomes.
== Select academic publications == Esimone is one of the most published scholars in Nigeria: His publications have been cited 7,402 times according to the AD Scientific index ranking, and 7,463 times according to the Google Scholar index. Here are a select few:
The discovery of nuclear fission occurred in 1938 in the buildings of the Kaiser Wilhelm Society for Chemistry, today part of the Free University of Berlin, following over four decades of work on the science of radioactivity and the elaboration of new nuclear physics that described the components of atoms. In 1911, Ernest Rutherford proposed a model of the atom in which a very small, dense and positively charged nucleus of protons was surrounded by orbiting, negatively charged electrons (the Rutherford model). Niels Bohr improved upon this in 1913 by reconciling the quantum behavior of electrons (the Bohr model). In 1928, George Gamow proposed the liquid-drop model, which became essential to understanding the physics of fission. In 1896, Henri Becquerel had found, and Marie Curie named, radioactivity. In 1900, Rutherford and Frederick Soddy, investigating the radioactive gas emanating from thorium, "conveyed the tremendous and inevitable conclusion that the element thorium was slowly and spontaneously transmuting itself into argon gas!" In 1919, following up on an earlier anomaly Ernest Marsden noted in 1915, Rutherford attempted to "break up the atom." Rutherford was able to accomplish the first artificial transmutation of nitrogen into oxygen, using alpha particles directed at nitrogen 14N + α → 17O + p. Rutherford stated, "...we must conclude that the nitrogen atom is disintegrated," while the newspapers stated he had split the atom.
Sources: en.wikipedia.org
== External links == UniProt: Bisphosphoglycerate mutase - Homo sapiens (Human) UniProt-Information about bisphosphoglycerate mutase A live model of the effect of changing 2,3-bisphosphoglycerate on the oxyhaemoglobin saturation curve
The 4n+2 chain of uranium-238 is called the "uranium series" or "radium series", the latter from the first member known when it was named, radium-226. The series terminates with lead-206, 8 alpha decays and 6 beta decays from uranium. The total energy released from uranium-238 to lead-206, including the energy lost to neutrinos, is 51.69 MeV; from californium-250, 68.28 MeV.
In this process, the signal, by interacting with the receptor, starts a series of molecular events within the cell leading to the final effect of the signaling process. Typically the final effect consists in the activation of an ion channel (ligand-gated ion channel) or the initiation of a second messenger system cascade that propagates the signal through the cell. Second messenger systems can amplify or modulate a signal, in which activation of a few receptors results in multiple secondary messengers being activated, thereby amplifying the initial signal (the first messenger). The downstream effects of these signaling pathways may include additional enzymatic activities such as proteolytic cleavage, phosphorylation, methylation, and ubiquitinylation. Signaling molecules can be synthesized from various biosynthetic pathways and released through passive or active transports, or even from cell damage. Each cell is programmed to respond to specific extracellular signal molecules, and is the basis of development, tissue repair, immunity, and homeostasis. Errors in signaling interactions may cause diseases such as cancer, autoimmunity, and diabetes.
== Early life == He is the fifth son of Sheikh Zayed bin Sultan Al Nahyan, the founder and first President of the United Arab Emirates. His mother is Sheikha Fatima bint Mubarak Al Ketbi and he has five full-brothers: Mohammed, Hamdan, Tahnoun, Mansour, and Abdullah.
Safrole is listed as a Table I precursor under the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Due to their role in the manufacture of MDMA, safrole, isosafrole, and piperonal are Category I precursors under regulation no. 273/2004 of the European Community. In the United States, safrole is currently a List I chemical. The root bark of American sassafras contains a low percentage of steam-volatile oil, which is typically 75% safrole. Attempts to refine safrole from sassafras bark in mass quantities are generally not economically viable due to low yield and high effort. However, smaller quantities can be extracted quite easily via steam distillation (about 10% of dry sassafras root bark by mass, or about 2% of fresh bark). Demand for safrole is causing rapid and illicit harvesting of the Cinnamomum parthenoxylon tree in Southeast Asia, in particular the Cardamom Mountains in Cambodia. However, it is not clear what proportion of illicitly harvested safrole is going toward MDMA production, as over 90% of the global safrole supply (about 2,000 tonnes or 2,200 short tons per year) is used to manufacture pesticides, fragrances, and other chemicals. Sustainable harvesting of safrole is possible from leaves and stems of certain plants, including the roots of camphor seedlings.
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.